Stuart A. Kingsley net worth and biography

Stuart Kingsley Biography and Net Worth

Director of Indivior

Tony Kingsley joined Indivior’s Board in July 2025. He has led organizations at every stage of biopharmaceutical development, from early research to global commercialization. As the former CEO of Stablix, Tony helped pioneer novel therapeutics in deubiquitination. His past leadership at Scholar Rock, TARIS Bio, The Medicines Company, and Biogen also reflect a consistent focus on advancing treatments for serious disease. Earlier in his career, he was a partner at McKinsey & Company.

Tony holds a magna cum laude degree from Dartmouth College and an MBA from Harvard Business School. His career has been defined by building teams that bring transformative science to patients.

What is Stuart A. Kingsley's net worth?: The estimated net worth of Stuart A. Kingsley is at least $173.66 thousand as of March 6th, 2026. Kingsley owns 5,582 shares of Indivior stock worth more than $173,656 as of March 13th. This net worth evaluation does not reflect any other assets that Kingsley may own. Learn More about Stuart A. Kingsley's net worth.
How do I contact Stuart A. Kingsley?: The corporate mailing address for Kingsley and other Indivior executives is 10710 Midlothian Turnpike, North Chesterfield, VA 23235, United States. Indivior can also be reached via phone at 804-379-1090 and via email at [email protected]. Learn More on Stuart A. Kingsley's contact information.
Has Stuart A. Kingsley been buying or selling shares of Indivior?: During the last ninety days, Stuart A. Kingsley has bought $29,948.40 of Indivior stock. Most recently, on Friday, March 6th, Stuart A. Kingsley bought 940 shares of Indivior stock. The stock was acquired at an average cost of $31.86 per share, with a total value of $29,948.40. Following the completion of the transaction, the director now directly owns 5,582 shares of the company's stock, valued at $177,842.52. Learn More on Stuart A. Kingsley's trading history.
Who are Indivior's active insiders?: Indivior's insider roster includes Keith Humphreys (Director), Stuart Kingsley (Director), Daniel Ninivaggi (Director), Barbara Ryan (Director), Mark Stejbach (Director), and David Wheadon (Director). Learn More on Indivior's active insiders.
Are insiders buying or selling shares of Indivior?: In the last twelve months, Indivior insiders bought shares 7 times. They purchased a total of 5,842 shares worth more than $203,342.45. The most recent insider tranaction occured on March, 9th when Director Barbara Ryan bought 31 shares worth more than $1,009.36. Learn More about insider trades at Indivior.
Information on this page was last updated on 3/9/2026.

Stuart A. Kingsley Insider Trading History at Indivior

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/6/2026	Buy	940	$31.86	$29,948.40	5,582

Stuart A. Kingsley Buying and Selling Activity at Indivior

Indivior Company Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Today's Range

Now: $31.11

$30.47

$32.18

50 Day Range

MA: $33.73

$30.86

$36.25

2 Week Range

Now: $31.11

$8.64

$38.00

Volume

13,297,327 shs

Average Volume

2,453,606 shs

Market Capitalization

$3.89 billion

P/E Ratio

18.97

Dividend Yield

N/A

Beta

0.83